Patent application number | Description | Published |
20080258833 | Signal Generator With Directly-Extractable Dds Signal Source - A signal generator including a DDS-signal source that is configured to operate according to the principle of direct digital synthesis (DDS), and a PLL signal synthesizer that is configured to operate according to the principle of phase locked loop (PLL) using an output signal from the DDS-signal source as a reference signal. The DDS-signal source can be connected via a direct connection, without further frequency division or mixing, directly to an output of the signal generator or directly to a level-adjustment device of the signal generator in order to generate a portion of an overall frequency range of an output signal of the signal generator. | 10-23-2008 |
20130314171 | SWITCHABLE FREQUENCY DIPLEXER CIRCUIT - An electronic circuit comprises a high-pass and a low-pass. The low-pass comprises at least one low-pass series element and a low-pass transverse element. The high-pass comprises at least one high-pass series element and a high-pass transverse element. The low-pass series element and the high-pass transverse element are realised in this context by a common component, and/or the high-pass series element and the low-pass transverse element are realised in this context by a common component. | 11-28-2013 |
20140347118 | ELECTRONIC SWITCH WITH COMPENSATION OF NON-LINEAR DISTORTIONS - An electronic switch contains an input terminal, and output terminal and at least one first switch element, which provides a voltage-dependent characteristic. In this context, the first switch element connects the input terminal to the output terminal in a selective manner. The electronic switch further comprises a compensation element, which provides a voltage-dependent characteristic. In this context, the compensation element is arranged in such a manner that it at least partially compensates the frequency-dependent characteristic of the switch element. | 11-27-2014 |
Patent application number | Description | Published |
20090010962 | Genetically Engineered Swine Influenza Virus and Uses Thereof - The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations. | 01-08-2009 |
20090042185 | Novel polymorphism in bovine prion protein gene sequence - A specific, non-synonymous SNP in the Prnp gene encoding the bovine prion protein affects the susceptibility of bovine animals to bovine spongiform encephalopathy (BSE). Depending on the number of octapeptide repeat units present in the Prnp gene, the position of the SNP is either nucleotide 631 of exon 3 (codon 211) when the Prnp gene comprises six octapeptide repeat region sequences, nucleotide 607 of exon 3 (codon 203) when the Prnp gene comprises five octapeptide repeat region sequences, or nucleotide 655 of exon 3 (codon 219) when the Prnp gene comprises seven octapeptide repeat region sequences. Alleles of the bovine Prnp wherein the SNP at these positions is lysine (K) at the corresponding amino acids (i.e., 211, 203 or 219) in the bovine prion protein are all indicative of increased susceptibility to BSE in comparison to alleles which encode glutamic acid (E) at the same position. This SNP may be used as a marker for selecting bovines susceptible to BSE for disposal and/or removal from breeding, the human food and animal feed supplies. | 02-12-2009 |
20130034581 | GENETICALLY ENGINEERED SWINE INFLUENZA VIRUS AND USES THEREOF - The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations. | 02-07-2013 |
Patent application number | Description | Published |
20110123999 | Novel Polymorphism in Bovine Prion Protein Gene Sequence - A specific, non-synonymous SNP in the Prnp gene encoding the bovine prion protein affects the susceptibility of bovine animals to bovine spongiform encephalopathy (BSE). Depending on the number of octapeptide repeat units present in the Prnp gene, the position of the SNP is either nucleotide 631 of exon 3 (codon 211) when the Prnp gene comprises six octapeptide repeat region sequences, nucleotide 607 of exon 3 (codon 203) when the Prnp gene comprises five octapeptide repeat region sequences, or nucleotide 655 of exon 3 (codon 219) when the Prnp gene comprises seven octapeptide repeat region sequences. Alleles of the bovine Prnp wherein the SNP at these positions is lysine (K) at the corresponding amino acids (i.e., 211, 203 or 219) in the bovine prion protein are all indicative of increased susceptibility to BSE in comparison to alleles which encode glutamic acid (E) at the same position. This SNP may be used as a marker for selecting bovines susceptible to BSE for disposal and/or removal from breeding, the human food and animal feed supplies. | 05-26-2011 |
20140212447 | Rift Valley Fever Virus Glycoproteins, GN and GC, and their Use - The present invention describes subunit vaccines containing Gn and Gc glycoproteins of the Rift Valley Fever Virus, including nucleic acids encoding such glycoproteins, host cells, vectors, and immunoreagents generated with the glycoproteins, methods of vaccination, methods of diagnosis, and kits. | 07-31-2014 |